Issue link: http://osercommunicationsgroup.uberflip.com/i/668578
C h a i n D r u g s t o r e D a i l y 3 3 S u n d a y, A p r i l 1 7 , 2 0 1 6 Executive Search, which helps you attract the best executive talent with the right fit; Korn Ferry Hay Group, which helps you align your organization and people, developing, engaging and rewarding them to achieve business suc- cess; and Korn Ferry Futurestep, which delivers professional talent with impact. Through combined strengths and specialized expertise in the life sciences and consumer practice areas, Korn Ferry has an unrivaled ability to address the entire talent continuum in North America as well as globally. It focuses on helping companies attract, develop and retain best-in-class talent. CDD: What would you say makes your company unique? JW: Unlike many companies, we are a supplier of human capital services. Our business model is a fit for manufacturers and retailers alike. Additionally, our range of capabilities is useful to services com- panies supporting the overall industry. Korn Ferry understands that human capi- tal is the differentiator between a good company and a great company. It drives the success of all businesses and is at a premium, in many cases, across the retail drug and manufacturing marketplace. CDD: What is your outlook for the next year? JW: We are very optimistic about our ability to serve our clients across multiple industries and are particularly proud of our ability to help our retail clients in addition to our clients across the pharma- ceutical and consumer products indus- tries. CDD: To what do you attribute your company's success? JW: Our success is driven by our ability to provide a broad suite of services that can cover almost any client request. This could come in the form of providing RPO services, entry level search services, mid- market needs as well as senior and exec- utive search services. From an overall K o rn Ferry (C o nt'd. fro m p. 1 ) talent management perspective, our abil- ity to bring professionals who are famil- iar with specific industries is proven within the marketplace. CDD: Why are your products or services the best value for your customers? JW: Korn Ferry has a diversified approach to talent services and develop- ment – we are able to provide a tailored solution for each individual client. This customized platform ensures our solu- tions are always an appropriate fit. None of our competitors can provide both the diversified product portfolio and the global outreach that Korn Ferry can deliver. CDD: How do your products or services enhance your customers' ability to com- pete in the marketplace? JW: Human capital is the most precious resource that any company has in its day to day operations. Without the right team in place, you cannot move a business for- ward no matter how strong your prod- ucts, your services or your locations. We consistently work on helping our clients improve their talent platforms, both existing within their companies as well as attracting new and greater talent to their companies. Our ability to do that gives our clients a leg up on the marketplace versus their competitors, and allows them the flexibility to build, grow and develop their company, products and services in an effective and efficient way. CDD: How do potential new customers know that they can trust you with their business? JW: With more than 45 years in the mar- ketplace, Korn Ferry has the most holis- tic, focused and time tested approach to overall talent solutions in today's market- place. Organizations around the world trust Korn Ferry to manage their talent – a responsibility we meet every day with passion, integrity and quality, resulting in longstanding client relationships. For more information, go to www .kornferry.com. industry, one that the U.S. Food and Drug Administration has been keeping a close eye on. With the change in times, compa- nies have come and gone, but none have made a splash quite like Nature's Truth. The Nature's Truth brand was intro- duced into the marketplace in 2014 by Scott Rudolph, Founder and Chief Executive Officer of Piping Rock Health Products. Rudolph has been a leader in the dietary supplement industry for more than 30 years; in fact, he grew up with the world of vitamins and supplements in the family. His father, Arthur Rudolph, founded Nature's Bounty (NBTY) and raised Rudolph to be the vitamin vision- ary he has proven to be. Today, Rudolph's son Michael sits beside him at Piping Rock, where he is passing on the values of running a business that is dedicated to delivering the highest quality, innovative products with the best value to customers. In just under a year, Nature's Truth has emerged as a frontrunner in the industry. The company has secured dis- tribution in more than 60 accounts across the country, with its diverse and innova- tive line of dietary supplements, aro- matherapy accessories and essential oils. The company has proven its success in providing incremental category growth in the vitamin aisle, especially since the Nature's Truth (C o nt'd. fro m p. 1 ) introduction of the Nature's Truth Aromatherapy product line. As the cost of healthcare continues to rise, consumers are looking to be proactive in their healthy lifestyles, rather than reactive. This means search- ing for alternative ways to support all areas of wellness, something dietary sup- plements have always had a hand in. However, lately it has also included adding aromatherapy into their daily rou- tines. By adding 100 percent pure plant based essential oils and versatile aro- matherapy accessories such as diffusers, base oils and roll-ons to the vitamin aisle, Nature's Truth has effectively brought in new shoppers to these categories and expanded their baskets. The team behind Nature's Truth has more than 40 years of experience in the nutritional supplement industry. The com- pany owns its own state-of-the-art manu- facturing facilities on Long Island in New York. By doing in-house what other com- panies outsource, it is able to oversee every step of the manufacturing process, guaranteeing quality and safety in all that they do while meeting or exceeding the strict standards set forth by the FDA. Nature's Truth follows GMPs and is stead- fast on the path to securing its spot as a pioneer in the latest supplement advances. For more information, visit booth #620. Even today, most consumers that visit the mouthwash aisle are still looking to purchase a bottle of mouthwash for the basic reasons that consumers have always bought mouthwashes. However, now that retail stores have become health and wellness centers, consumers are looking to retail stores to carry medical, wellness or health solutions where tech- nology and science might be the signifi- cant reason why a consumer walks into the store to purchase a given item, and not so much the more general CPG area how its classified. So for that reason, a one-size-fits-all approach to SKU ration- alization in any given category might be erroneous. Let's look at an example. David Biernbaum, 37-year veteran of oral care consumer products market- ing and retail merchandising, explains that even though the word "mouthwash" appears prominently on every dual-pour bottle of SmartMouth, and albeit the products appear in the mouthwash modu- lar, and IRI tracks the brand against all over mouthwash SKUs, it could be argued that SmartMouth just happens to be a mouthwash, but isn't necessary being purchased in the traditional sense of why consumers buy mouthwashes. SmartMo uth (C o nt'd. fro m p. 1 ) Halitosis, or bad breath, is a condi- tion that afflicts millions of people, and severely impairs quality of life in so many ways, on so many levels. Long ago, science experts determined that a combination of two separate solutions delivered to the mouth in the form of mouthwash rinse might be more efficient than medications, tablets, inhalation, droplets or injection. So, SmartMouth is found in the mouthwash aisle. But SmartMouth is a science, a system and a clinically proven technology, delivered in the form of two separate solutions, one which activates the other, in the form of a dispensing dual-chamber single unit bot- tle, found in the mouthwash section of pharmacies and wellness centers. According to David Biernbaum, the SmartMouth brand is having a very strong year and continues to grow, with POS numbers climbing, with well-above average price points, margins and shelf productivity, and a coveted destination minded consumer that spends nearly 50 percent more dollars than the average consumer that shops the store. For more information, contact David Biernbaum at 314.434.6008 or dbiernbaum@smartmouth.com, or visit www.smartmouth.com. PAIN THERAPEUTICS RESUBMITS REMOXY TO FDA Pain Therapeutics, Inc. announced today that it has resubmitted to the U.S. Food and Drug Administration (FDA) a New Drug Application (NDA) for REMOXY ® , an abuse-deterrent formula- tion of extended-release oxycodone (CII) capsules. Pain Therapeutics expects to be notified by the FDA of a Prescription Drug User Fee Act (PDUFA) action date within 30 days. The original REMOXY NDA has a Priority Review designation. REMOXY is a proprietary drug developed and owned by Pain Therapeutics. The drug candidate's pro- posed indication is for "the management of pain severe enough to require daily, around-the-clock, long-term opioid treat- ment and for which alternative treatment options are inadequate." Pain Therapeutics specifically devel- oped REMOXY to make oxycodone dif- ficult to abuse yet provide 12 hours of steady pain relief when used appropriate- ly by patients. In particular, REMOXY's thick, sticky, high-viscosity formulation may deter unapproved routes of drug administration, such as injection, snorting or smoking. Pain Therapeutics owns exclusive, worldwide rights to REMOXY. About Opioid Abuse Opioid drugs such as oxycodone are an important treatment option for patients with severe chronic pain. However, oxy- codone abuse and diversion remains a serious, persistent problem. Nearly 19,000 people died from opioid overdose in 2014, according to the National Institute on Drug Abuse. For more than a decade, Pain Therapeutics has pioneered Abuse-Deterrent Formulations (ADFs) to help in the fight against prescription drug abuse. ADFs attempt to raise the bar on prescription drug abuse by making it dif- ficult, longer or aversive to tamper with long-acting opioid formulations, recog- nizing that no drug can be made abuse- proof. About Pain Therapeutics, Inc. Pain Therapeutics develops proprietary drugs that offer significant improvements to patients and physicians. Its expertise consists of developing new drugs and guiding these through various regulatory and development pathways in prepara- tion for their eventual commercialization. It generally focuses its drug development efforts around disorders of the nervous system, such as chronic pain. The FDA has not yet established the safety or effi- cacy of its drug candidates.